Business Context and Reporting Period
Company: Compugen Ltd. (CGEN)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Compugen is a clinical-stage therapeutic discovery and development company utilizing its AI/ML-powered computational discovery platform, Unigen, to identify novel drug targets in immuno-oncology. The company has no approved products and relies on collaboration agreements for revenue.
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $72.8 million | $27.9 million | $33.5 million |
| Net Profit (Loss) | $35.3 million | ($14.2 million) | ($18.8 million) |
| Operating Profit (Loss) | $31.3 million | ($14.9 million) | ($13.0 million) |
| Research & Development Expenses | $22.8 million | $24.8 million | $34.5 million |
| Cash and Cash Equivalents | $90.6 million | $18.2 million | $13.9 million |
| Total Liquidity (Cash, Deposits, Securities) | $145.6 million | $103.3 million | N/A |
| Accumulated Deficit | ($453.4 million) | ($488.8 million) | N/A |
| Outstanding Shares | 94,553,191 | 89,541,246 | N/A |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net profit of $35.3 million in 2025, reversing a net loss of $14.2 million in 2024. This shift was primarily driven by a $65 million upfront payment received from AstraZeneca following an amendment to their license agreement.
- Revenue Surge: Revenue increased 161% year-over-year to $72.8 million. The increase is attributed to the AstraZeneca upfront payment and revenue recognized from the Gilead license agreement (Phase 1 services).
- Liquidity Improvement: Total liquidity increased to $145.6 million from $103.3 million in 2024, bolstered by cash inflows from partnerships and an "at-the-market" (ATM) equity offering which generated approximately $10.5 million in net proceeds in 2025.
- Expense Management: R&D expenses decreased by 8% to $22.8 million due to the winding down of prior clinical trials, partially offset by costs for the new MAIA-ovarian trial.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Cash Runway: Management believes current cash, cash equivalents, and marketable securities are sufficient to fund operations into 2029 based on current plans, excluding potential future funding from collaborations or financings.
- Pipeline Focus: The company is highly dependent on the success of four clinical-stage programs: COM701 (anti-PVRIG), COM902 (anti-TIGIT), rilvegostomig (AstraZeneca partner), and GS-0321 (Gilead partner).
- Strategic Shift: Due to recent negative data in the TIGIT field (including failures by competitors), the company currently believes COM902 has limited near-term value and does not plan to initiate new clinical trials with it, though this may be revisited.
- Key Milestones: An interim analysis for the MAIA-ovarian trial (COM701) is expected in the first quarter of 2027.
Material Risks and Contingencies
- Geopolitical Instability: Operations are headquartered in Israel. Ongoing conflicts in the Middle East, including hostilities involving Iran and regional proxies, pose risks to operations, employee availability (reserve military service), and supply chains.
- Collaboration Dependency: Revenue is heavily reliant on two partners: AstraZeneca (rilvegostomig) and Gilead (GS-0321). Termination of these agreements or failure of the underlying assets would materially harm the business.
- Clinical Trial Risks: High risk of failure in clinical trials, patient enrollment challenges, and potential delays. Preliminary data may not predict final results.
- Intellectual Property: The company faces ongoing patent opposition proceedings in Europe regarding its anti-PVRIG antibodies.
- PFIC Status: The company believes it was a Passive Foreign Investment Company (PFIC) for 2025, which may have adverse tax consequences for U.S. shareholders.
Investor Verification Checklist
- Revenue Recognition: Verify the accounting treatment of the $65 million AstraZeneca upfront payment and the allocation of the Gilead transaction price between license and service obligations.
- Cash Runway Validity: Assess the sustainability of the "into 2029" cash runway projection given the high burn rate of clinical development and potential for increased costs.
- COM902 Strategy: Confirm the rationale for pausing new COM902 trials and the potential impact on the AstraZeneca partnership value.
- Geopolitical Exposure: Review the specific impact of the Israel/Middle East conflict on clinical trial enrollment in Israel and employee retention.
- Patent Litigation: Monitor the status of the European Patent Office (EPO) opposition proceedings regarding anti-PVRIG patents.